Them olecular basis of haemophilia Bi sh eterogeneous and manymutations of the Factor IX (FIX) gene have been characterised.U sing the allele-specific arrayedp rimere xtension (AS-APEX)t echnology, we have designed aF IX arrayt os imultaneously analyse 69 mutations found in British,Thai and Chinese patients.This technologyovercomesthe problem of multiple reverse dot-blotanalysis and has a100% accuracyinthe detection of both affectedsubjects and carriers in familieswith knownmutations.Ins even unknown mutations from Thailand, thea rray could detect the specific mutation in fiveand in the remainders Keywords Haemophilia B, FIXmicroarray,AS-APEX,FIX mutations the normal primeratspecificspotsfailed to extend due to amutationafew nucleotides upstream, thus allowing their identification. Hence this FIX arraycan detect 53%ofthe 2891 mutation entriesinthe FIX database.Each of themicroarray slidecan be usedfor threedifferenttestsamples and would be useful forcarriert esting forc ommon mutations and prenatal diagnosis. It is simpler and morec ost effectivet han genomes equencing and would be particularlyu seful in laboratories withl imited technical capabilities.
Introduction
Haemophilia B( Christmas Disease) is an X-linked coagulopathy due to deficiencyofthe clotting factor IX (FIX) (1) . It affectsa pproximately1i n2 5,000 -3 0,000 live-born males ( 2) , usuallyfemales with one defective gene areasymptomatic carriers. Them olecular basis of the disease is heterogeneous and over 900mutations have beencharacterised (3) .While anumber of restriction fragment length polymorphisms( RFLPs) can be used forlinkage of the affected geneinCaucasians (4), in Orientals, wholack heterozygosity for these RFLP sites(4-6), carrier detection and prenataldiagnosis are mainlyperformed by direct mutation detection (5) .
The development of microarraytechnology (7) has enabled large-scalesequence analysis or mutation detection. Employing the allele-specific arrayedp rimere xtension (AS-APEX) technology,wehaverecently devised amicroarrayfor simultaneous analysis of multiple mutations of the α -and β -globin genes (8) . We nowa pplyt he same technology for the manufacture of a microarrayfor detecting FIX mutations in known mutants from threepopulations as well as thosethat had beenrecorded three or moretimesonthe FIX database.This microarray should be particularlyusefulfor detection of common mutations,carrier testing in familym emberso fk nown indexp atients and in subsequent prenatal diagnosis.
Materials andmethods
Genomic DNAwere prepared fromperipheral blood leucocytes of 69 unrelated Haemophilia Bpatients (68 malesand 1female withFIX =0.08 iu/ml), 12 known carrierfemales and 1normal female by aphenol-chloroformextraction method (9) .These patients were attending the Haematologyclinicsateitherthe Queen MaryH ospital, Hong Kong; the Ramathibodi Hospital, Bangkok, Thailand or the Royal Free Hospital, London, UK.The genotype of the patients had beendeterminedpreviouslybydirect genomic sequencing, butthe resultswere blindedtothe scientist performing the microarray analysis.
To furthervalidate the usefulnessofthe fabricatedFIX array, DNAs amples from7u nrelated,n ew haemophilia Bp atients (mutationsu nknown) and 49 females (38 were relatives of knownmutants and 12 were from newhaemophilia Bfamilies) were sentfrom Thailand.The status of these samples were unknown to the Hong Kong group and to the laboratorypersonnel performing the microarrayanalysis.
All chemicals and solvents were of analytical grade purchased fromSigma-Aldrich (St. Louis, MO,USA)unless noted otherwise. Cyanine-labelled deoxycytosine triphosphate (Cy5-dCTP) waspurchasedfrom Amersham PharmaciaBiotech (Piscataway,N J, USA). Pre-cleaned,n on-derivatisedg lass microscopes lides( 25 x7 5mm 2 )w ere purchased fromV WR Scientific (San Francisco, CA, USA) and LifterSlips were from ErieScientific (Portsmouth, NH,USA).
Preparation of slides and arrayprinting
The slides were prepared for printing and the oligonucleotide primers, approximately 56 basepair in length, with phosphorothioate incorporated at the 5'terminus and the allele-specific nucleotide at the 3' terminus were synthesized as described previously ( 8, 10) . The oligonucleotide primersw ere designedt o allowd etection of known mutations in our initial6 9p atients (primers equences are availableo nr equest).T he oligonucleotides were dissolvedin1xspotting solution (Telechem, Sunnyvale,CA, USA) at twoconcentrations of 5and 2 µ Mrespectively and spottedonto the slide by contact printing with 'chipmaker' pins (Cartesian, Irvine, CA,USA)onthe arrayer(Prosys gantry 5510, Cartesian).Each slide contains three sections of oligonucleotidesfor analysis of threedifferent test samples. In addition, in each section, the oligonucleotidesw ere spottedintriplicate. After spotting, the slides were left overnighti nt he humid chamber to allowthe oligonucleotides to bind onto the glass surface.
Te mplatepreparation
Single-stranded template for allele-specificp rimere xtension wasgenerated by asymmetric amplification of the FIX gene in 7 fragmentsu sing either5 0n g( Exons 1, 4, 5a nd 6) or 150 ng (Exons 2+3, 7and 8) of genomic DNAina50 µ lreaction volume containing 1xP CR buffer (10m MT ris-HCl pH 8.3, 50 mM KCl), 3.5 mM MgCl 2 ,4 0n Mf orwardp rimer, 200 nM reverse primer, 200 µ Mofeach dNTP and 0.5xBDTitanium Taq(BD Biosciences Clontech, Palo Alto,CA, USA). After an initial hotstartof95°C x30sec, 50 cycles amplification of 95°C x10sec, 54°C x20sec and 68°C x40sec were performed,with afinalextension timeof7min.
All asymmetric-PCR (A-PCR) products were pooled,e thanol precipitated and resuspendedi n2 4 µ lw ater and columnpurified (Auto-seqG 50, Amersham Pharmacia Biotech, USA) to remove unincorporated dNTPS.H alfo ft he A-PCRp roduct wasdried and resuspended in 5 µ lofwater forthe analysis.
Allele-specific arrayedprimer extension (AS-APEX)
To reduce non-specificbinding, the arrayedslide waspre-incubated in 20 µ lof1xPCR buffer under aLifterSlip (ErieScientific,USA)inthe hybridization cassette (Telechem, USA). The entire assembly wassubmerged in a60°C waterbathfor 30 min.
The slides were rinsed with water, spun dryat110 gx8min, then overload with the AS-APEXr eaction mix, containing A-PCR product,0 .25 µ Mo fe ach dATP,d GTP,d TTP,C y5-dCTP and 0.125 µ Md dNTP,0 .75 xT itanium TaqP olymerase,1 0m M Tris HCl, 50 mM KCl, 1mM MgCl 2 and 4% DMSO in atotal volume of 15 µ l. Theentire cassette assembly containing the array and LifterSlips were transferred to a75°C waterbathfor 7min, to activate the Titanium TaqPolymerase.The AS-APEX reaction wasthen allowedtoproceed for afurther 30 min in a60°C waterb ath. Ther eaction wast erminatedb yr insingt he slides threetimeswith wateratroom temperatureand in wash solution (0.5 xS SC and 0.03%s odium dodecyl sulphate) (1 xS SC = 0.3M NaCl,0.03M sodium citrate) at 80°C for 2min, thenrinsed in 0.05xS SC. After centrifugation (110 gx8m in),t he slides were scanned at an emission wavelength of 670 nm and 10 µ m resolution for the detection of incorporated Cy5-dCTP (ScanArray5000, GSI Lumonics, Boston, MA, USA).
Results
AF IX microarraya llowingt he detection of 69 mutations was fabricated. Initially, the arraywas testedon82samples from69 unrelated Haemophilia Bpatients whose mutations were already known and 13 of their female familymembers. The results are shown in table 1. The mutations in 35 British, 22 Thaia nd 12 Chinese patients were correctlyidentified (accuracy =100%).At the same time,12femalecarriers and 1normal female were correctlyidentified.
The sample from ahaemophiliacpatient carrying amutation nt 30929 A → T, gave apositivesignalwith the mutant oligonucleotide primer, butfailedtoextend (no signal) with both the normalprimerfor nt 30929 and nt 30933 (Fig. 1A ).Similarresults were observedfor samples from patients carrying amutation in close proximity to the next one, e.g., sample with nt 6mutation failedtoextend the normal primer at nt 6and nt 8 (Fig. 1C) .
Validation of the arrayusingunknown samples
To test the usefulnesso ft he array, af urther 56 DNAs amples were sentfrom Thailand.Therewere 49 females,37were relatives of patients with known FIX mutations.1 4o bligatec arriers were correctlyidentified and 14 out of 23 possible carriers were identifiedascarriers by arrayand confirmed by sequencing. The remaining nine possible carriers foundt ob en ormal by array analysis were subsequently confirmed as normal by genomic sequencing of their FIX gene.FIX:Clevel of the normalfemales were 51-90% whilst thato ft he carriers were 40-130% ( Table  2A) .12females were relatives of the 7new haemophilia Bpatients whose mutations have not beencharacterised. FIX:C level had onlybeen measured in fourofthese subjects (60-134%). Of these,four had their carrierstatus and mutation identifiedfrom the arrayanalysis, and subsequentlyconfirmed as correct by genomic sequencing. Forseven females whowere foundtobenormalo ni nitial arraya nalysis, sequencing of all eight exons of their FIX gene and the immediate 5' and 3' splice junctions did not reveal anymutations. The remaining case (N83) wasidentified as ac arrier by sequencing, with am utation at nt 6365 (G→ T), whichwas notspotted on our array(vida infra).
DNAsamples of the sevennew haemophilia Bpatients were analysed. Thec ausativem utations of five patients were identifiedbyarray analysis (Table 2B ) and confirmed by sequencing. In the remaining twopatients, their DNAfailedtoextend the normals equence at nt 20519( G → A) (N67) and nt 6365( G → A) (N84) respectively,this indicatedthat their FIX mutation lies at or immediatelyupstreamtothose regions. Genomic sequencing of their FIX gene revealed anew mutation at nt 20518(C → T) and nt 6365 (G→ T) respectively (Fig. 2) .Inthe latter case, his female relative(N83) wasalso found by sequencing to be acarrier. 
Discussion
In the currentFIX array, we have spottedoligonucleotidesfor the detection of 69 mutations simultaneously. The majority of these mutationshad been reportedatleastthreetimesinthe FIX database,w hile othersw ere usefulf or detection of defects in Haemophilia Bp atients attendingt he Haematology clinic at our threecentres.Onatheoreticalbasis, anynumber (up to 8,000) of different oligonucleotide primersc an be designeda nd spotted onto the array, if the entiresurfaceofthe slide (50 x20mm) is usedfor arraying and singletestsampleanalysed on each slide. With the AS-APEXtechnologyusedinour arraysystem, strand synthesis will onlyoccur with aperfectly matchedoligonucleotide and no stringent washing is needed to remove unstable complexa si na llele-specific oligonucleotide (ASO) hybridization, whichisthe basis of the reverse dotblot (RDB)system. In comparison, RDB requirest hat the oligonucleotide probesb ed esignedt oa llowh ybridization and stringent washing fora ll the normaland mutant probesatthe same temperature (11) . Thus it would be impossible to design aRDB to detect theover900 mutations presentlyidentified for the FIX gene.
Since only 0.9 nl of oligonucleotide is arrayedonto each spot and the glass slide canbeeasilyprepared for spotting, the costof preparing our current FIX arrayin-house is approximately US$ 3.00. The arraycan thenbeusedtoanalyse threetestsamples.It is possible to generate single stranded template for the ASAPEXr eaction directly from genomic DNAb ya djusting the asymmetric primers' concentration. In our hands, despite the number of amplification cycles needed,t aking standard PCR precautions as in most routine laboratories that handle patient samples, no contamination or 'artificial'generation of mutations have beenencountered. The cost of asampleanalysis, including PCRr eagents, AS-APEXr eagents uch as Cy5-dCTP and Titanium TaqPolymerase is US$ 8.10. This is much cheaperthan the cost of automatedsequencing of the whole gene (US$ 90 for unknown mutation detection, US$ 18 for subsequent carrierdetection).Evenifthe known mutation altersanenzyme recognition siteand PCRfollowedbydirect restriction analysis is possible, the analysis usingthe FIX arraywould be less time-consuming, as the entire procedureofPCR and arrayanalysis takes no more than six hours and also avoids the use of ethidium bromide for gel-staining whichishazardoustothe laboratorystaff.
Figure1
:FIX arrayafter hybridization of amplifiedgenomicDNA from haemophilia Bpatients. Thenormal and mutant oligonucleotide primers were spotted in triplicateand at twoconcentrations, hence thepositivesignals after theAS-APEX reactionwereofdual intensity.a)patient with mutation at nt 30929, b) Afemale patient who is heterozygousfor thedefectbut has haemophiliadue to skewed inactivationofher normal X chromosomeand c) patient withdefectatnt6. 
Ta ble2B: Mutationdetection for7newhaemophilia Bpatients.
Previous experienceh as shown thatt he spotted arrays are stable, can be storedatroom temperatureand areusablefor at least six months.Thus it would be possible to have the arrayprepared in asingle place and shippedtootherlaboratoriesfor use, making it unnecessary for each laboratoryt om aket heir own array. The onlyrequirement thenwould be athermocyclerand a lasers canner ford etection of emission at aw avelength of 670 nm. This FIX arrayshould be particularly useful for laboratories in some developingcountries whomay not wish to go to the expense of establishingh igh-throughouts equencing.T he technique is relatively simple, includesgeneration of single-stranded template directly by PCR, performing the AS-APEXreaction on the array, single washing step and laserscanning. It would take less thanasingle working daytoperform and is relativelycheap at aroundUS$ 10 for asingle sample analysis.
We have testedt his FIX arrayi nitiallyo ns amples from6 9 unrelated haemophilia Bp atients from England,Thailand and Hong Kong (whose mutations arek nown and arrayedo nt he slide) and some of their female familym embers( Table1 ). It showed 100% accuracy. In AS-APEX technology, the allele-specific nucleotide is at the 3' terminus,resulting in extensionand formation of acoloured(Cy5-labelled) extendedproduct with a perfectlym atched oligonucleotide primer. Thus the absenceo f coloured product (signal) with the normalo ligonucleotide primerusuallyindicates 'homozygosity' or in case of asample from the male patient, 'hemizygosity' or affected subject.O ne male with haemophilia had amutation at nt 30929 A → T, butdid not extend both its ownnormal oligonucleotide sequence as well as the normalsequence at nt 30933. Thelatterw as most likely due to the formation of a'bubble',wherethe mismatch occurred fournucleotides upstream, resulting in an unstable annealment betweenp rimera nd template and therefore,n oe xtension (Fig.  1A) .This also explains the absence of extensioninanother patient with nt 6mutation, for the normal sequence at nt 8that lies twon ucleotides downstream from the mutation under analysis (Fig. 1C) .
To validate the usefulnessofthe microarray,w eanalysed a further5 6s amples fromp atients and familym embersf rom Thailand.Asexpected,all 37 females from familieswith known mutation hadt heir carriers tatus correctly determinedb yt he array. Furthermore, in the sevenn ew haemophilia Bf amilies, five had mutations detectablebythe arraywhile in the remaining two, their mutation waslocalized to the vicinity of aspecific spot on the array. As discussed previously,t his wasd ue to the formation of an unstable complexbetween the 'mutant'template and the normaloligonucleotide primerafew nucleotide downstream, thus resulting in the absence of extension. Indeed,t his wasdemonstrated in asamplefrom anew Thai Haemophilia B patient (N67) (Fig. 2) . His DNAdid not give anyextension product with either the normal or mutant primersatnt20519. Whilst this indicatedthat he did not carrythe nt 20519 G → Adefect,it meant thatt he mutation could be in the vicinity.G enomic sequencing of exon fofhis FIX gene confirmed amutation at nt 20518 C → T.
Thus it would be possible to use this arraysystem as an initial screening technique for newHaemophilia Bpatients, to identify the causativemutation or to localize the region of the mutation along the gene.I fu ndetectedo nt he array, thenc onventional genomic sequencing of that particular exonic fragment will be performed. Based on this approach, the current array fabricatedwith 69 oligonucleotide primersetswill allowdetection of 1537out of the 2891 (53.1%)entries in the FIX database.
Obviously it is possible to make acomprehensive arraytodetect allthe entries (for over 900FIX mutations)but it will be more expensive.
